Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02171221 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Oral DFP-11207 in Solid Tumors
A Phase 1 study, sponsored by Delta-Fly Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02171221: Completed Phase 1 study, sponsored by Delta-Fly Pharma.
NCT02171221 is a Phase 1 study that has completed, run by Delta-Fly Pharma. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02171221, a Phase 1 study, has completed, sponsored by Delta-Fly Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a first-in-human, open label, single arm, sequential dose escalation and expansion study of oral DFP-11207 in patients with advanced solid tumors.
Primary Outcome
The MTD and tolerability will be based on the incidence of adverse events and dose-limiting toxicities in patients. CTCAE 4.0 will be used to grade the severity of adverse events.
Interventions
- DRUG Oral DFP-11207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-09-13 |
| Phase | Phase 1 |
What the finished NCT02171221 record still lists
NCT02171221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Oral DFP-11207 is the first listed.
NCT02171221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02171221 about?
NCT02171221 is a clinical study titled "Phase I Study of Oral DFP-11207 in Solid Tumors". This is a first-in-human, open label, single arm, sequential dose escalation and expansion study of oral DFP-11207 in patients with advanced solid tumors.
What is the current status of trial NCT02171221?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2014-06. Estimated completion is 2018-09-13.
What interventions are being tested in trial NCT02171221?
The interventions under investigation include: Oral DFP-11207 (DRUG).
Who is sponsoring clinical trial NCT02171221?
This trial is sponsored by Delta-Fly Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02171221's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia